Please assess the completion status of the following clinical trial:

Trial Title: Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal, hormone receptor-positive patient~* Histologically verified (minimally) invasive breast cancer, local radical treatment~* 0-9 involved axillary lymph nodes (≥ 10 histologically examined nodes)~* Tumor stage: pT1b-3, yT0 or yT1a~Exclusion Criteria:~* T1a, T4d, yT4; M1~* Previous breast tumor irradiation~* Previous or concurrent chemotherapy (except for preoperative chemotherapy)~* Serum creatinine \> 1.5 x UNL or creatinine clearance \< 60 ml/min

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- AZ (Arimidex+Zoledronate) (Type: ACTIVE_COMPARATOR): Study Drugs Arimidex (Anastrozole), Zometa (Zoledronate; zoledronic acid)
- TZ (Tamoxifen+Zoledronate) (Type: ACTIVE_COMPARATOR): Study Drugs Nolvadex (Tamoxifen), Zometa (Zoledronate; zoledronic acid)
- AC (Arimidex Control) (Type: ACTIVE_COMPARATOR): Study Drug Arimidex (Anastrozole)
- TC (Tamoxifen Control) (Type: ACTIVE_COMPARATOR): Study Drug Nolvadex (Tamoxifen)

Based on this trial design, predict the completion outcome and termination type (if applicable).